Cyclerion Therapeutics, Inc. (CYCN)

Cyclerion Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3.01	3.23	7.57	13.38	53.96	54.4
Cash & Short-Term Investments	3.01	3.23	7.57	13.38	53.96	54.4
Cash Growth	-34.48%	-57.31%	-43.42%	-75.20%	-0.80%	-42.68%
Accounts Receivable	0.53	0.56	-	0.1	0.1	-
Other Receivables	-	-	-	-	-	0.13
Total Trade Receivables	0.53	0.56	-	0.1	0.1	0.13
Other Current Assets	0.49	0.44	0.45	1.34	1.4	3.98
Total Current Assets	4.02	4.23	8.02	14.82	55.46	58.5
Net Property, Plant & Equipment	-	-	-	1.22	1.47	50.27
Long-Term Investments	5.35	5.35	5.35	-	-	-
Other Long-Term Assets	-	-	-	2.04	2.41	6.61
Total Assets	9.37	9.58	13.37	18.08	59.33	115.38
Accounts Payable	0.46	0.39	1.2	2.97	1.83	1.44
Accrued Expenses	0.34	0.34	0.89	4.66	9.26	8.72
Short-Term Debt	-	-	-	-	-	3.51
Current Portion of Leases	-	-	-	-	-	3.29
Total Current Liabilities	0.8	0.73	2.09	7.63	11.09	16.95
Long-Term Leases	-	-	-	-	-	38.93
Total Long-Term Liabilities	-	-	-	-	-	38.93
Total Liabilities	0.8	0.73	2.09	7.63	11.09	55.89
Additional Paid-in Capital	277.82	276.34	275.72	269.63	263.35	222.95
Accumulated Other Comprehensive Income	-	-	-0.01	-0.02	-0.02	-0.03
Retained Earnings	-269.25	-267.49	-264.42	-259.15	-215.08	-163.43
Shareholders' Equity	8.57	8.85	11.29	10.45	48.25	59.49
Total Liabilities & Equity	9.37	9.58	13.37	18.08	59.33	115.38
Total Debt	0	0	0	0	0	45.74
Net Cash (Debt)	3.01	3.23	7.57	13.38	53.96	8.66
Net Cash Growth	-6.99%	-57.31%	-43.42%	-75.20%	523.11%	-58.71%
Net Cash Per Share	1.12	1.28	3.24	6.16	27.57	5.70
Book Value	8.57	8.85	11.29	10.45	48.25	59.49
Book Value Per Share	3.21	3.51	4.83	4.81	24.65	39.14
Tangible Book Value	8.57	8.85	11.29	10.45	48.25	59.49
Tangible Book Value Per Share	3.21	3.51	4.83	4.81	24.65	39.14

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q